Sou Hu Cai Jing·2026-01-30 06:19Group 1 - Goldman Sachs has adjusted the profit forecasts for Tigermed (03347.HK) for 2025 to 2027, decreasing by 29%, increasing by 2%, and increasing by 2% respectively [1] - The target price for Tigermed's H-shares has been slightly raised from HKD 63.4 to HKD 66.4, while the target price for its A-shares has increased from RMB 78.7 to RMB 82.5, both maintaining a "Buy" rating [1] - There has been low attention from investment banks on this stock, with no ratings given in the past 90 days [1] Group 2 - Tigermed's market capitalization in the Hong Kong stock market is HKD 58.83 billion, ranking 12th in the healthcare services sector [1] - Key performance indicators for Tigermed compared to the industry average are as follows: - ROE: 1.45% vs. industry average of 1.62%, ranking 32nd [1] - Market capitalization: HKD 58.83 billion vs. industry average of HKD 85.19 billion, ranking 12th [1] - Revenue: HKD 64.95 billion vs. industry average of HKD 39.01 billion, ranking 7th [1] - Net profit margin: 11.16% vs. industry average of -963.25%, ranking 12th [1] - Gross profit margin: 30.09% vs. industry average of 41.13%, ranking 32nd [1] - Debt ratio: 15.93% vs. industry average of 74.33%, ranking 8th [1]